(Yicai Global) April. 24 -- Listed Chinese drugmaker Porton Pharma Solutions Ltd. and US-based biomedical company Codexis Inc. have partnered to develop more efficient biocatalysts, which are enzymes that increase the rate of chemical reactions in a body.
The two medical tech firms signed a five-year global partnership, in which Codexis will provide preferential access to its protein engineering platform CodeEvolver for Porton to develop more efficient biocatalysts, the Chongqing-based firm said.
The two parties will use the platform to provide global pharmaceutical companies with comprehensive biocatalyst solutions, including screening, development, trials and commercial production, the statement said without disclosing financial details.
Enzymes, a kind of biocatalyst, dictate the body’s many catalytic processes such as metabolism and energy-conversion.
Editors: Emmi Laine, William Clegg